QPharma Appoints Director, DEA Compliance and Services

MORRISTOWN, N.J.--(BUSINESS WIRE)--QPharma, Inc., a leading compliance and commercial solutions firm serving the life sciences industry, has announced the appointment of Matt Crusan to the position of Director, DEA Compliance and Services. A former Diversion Investigator with the Drug Enforcement Administration (DEA), Crusan brings his extensive knowledge of DEA regulatory policy to his role as head of QPharma's newly established DEA compliance practice.

"I look forward to contributing to the continued growth and success of the company and its clients."
In addition to his work with the DEA, Crusan has experience conducting enterprise-wide DEA gap analyses and development of Suspicious Order & Monitoring (SOM) programs for drug wholesalers and manufacturers. Among Crusan's specialties is the development of procedures and training to help pharmaceutical firms educate staff and minimize the risks associated with regulatory non-compliance. Most recently, Crusan served as Director of Regulatory Affairs for the Pharma Compliance Group, where he provided DEA compliance consulting services to manufacturers, distributors, hospitals, and retail pharmacy chains.

The new DEA compliance practice at QPharma will include a suite of solution offerings, such as mock DEA audits and inspections, due diligence/diversion analysis, Standard Operating Procedure review, and physician risk analysis.

"QPharma already has a sterling reputation in this area, through its provision of controlled-substance sample distribution at its DEA-registered fulfillment center," said Crusan. "I look forward to contributing to the continued growth and success of the company and its clients."

"Matt's outstanding credentials and breadth of experience speak for themselves," said QPharma President and CEO Patrick P. Den Boer. "We are pleased to welcome him to our Professional Services team."

About QPharma, Inc.

QPharma provides a suite of services and solutions to the life sciences industry. Services offered by the company's Professional Services division include complete validation services, project management, auditing, and training. The Commercial Services division provides solutions in such areas as aggregate spend reporting, PDMA compliance, online training, warehousing and fulfillment, and brand marketing and sales support. The company's engineers, regulatory compliance experts, and brand consultants have been proudly serving the life sciences industry since 1994. To learn more, visit www.qpharmacorp.com.

Contacts

QPharma, Inc.
Brendan Middleton, 973-656-0011, Ex. 2112
Director of Marketing and Public Relations
[email protected]
 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.